Startup profile · funding coverage
Novadip Biosciences funding, valuation and investors
Regenerative-medicine biotech that raised €10.4 million of convertible financing to complete a pivotal Phase 3 trial.
Keep track of Novadip Biosciences
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Convertible financing
€10.4M · September 21, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · Mont-Saint-Guibert, Belgium
Investors in latest funding
Lead: New Science Ventures
Other: Fund+ , Wallonie Entreprendre , VIVES Fund
Overview
Novadip Biosciences develops regenerative medicine products for severe bone defects. On September 21, 2026 the company announced €10.4 million ($11.98 million) of convertible financing led by New Science Ventures, bringing convertible financing since June 2025 to €20 million.
Why Novadip Biosciences is interesting
Late-stage clinical financing with a clearly disclosed convertible structure; useful for VCT's biotech database even though search demand is modest.
Key facts
- Sep 21, 2026: €10.4M convertible financing
- Total convertible financing since June 2025: €20M
Funding history (newest first)
Convertible financing
2026-09-21 €10.4M- New Science Ventures (lead)
- Fund+ (participant)
- Wallonie Entreprendre (participant)
- VIVES Fund (participant)
Market / IPO context
Editorial / static context — not a live quote.
FAQs about Novadip Biosciences
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.